Turkan PATİROGLU, Murat CANSEVER, Fulya BEKTAS KUT

A pilot study about subcutaneous administration of 10% immunoglobulin in patients with primary immune deficiencies: Single center experience

Aim: In this study, we aimed to see the safety, protectivity and adverse events of rapid infusion subcutaneous immunoglobulin (SCIG) therapy in our patients for one year duration.Material and methods: 10 patients diagnosed with primary immune deficiency and receiving regular intravenous immunoglobulin (IVIG) were randomly included to the study, then their IVIG replacement therapy changed as rapidly infused SCIG in same monthly dose. Patients were evaluated in different times for following aspects; serum IgG levels, frequency of infections, side effects, localreactions, and improvement of life quality. IgG levels of patients were measured at the beginning, 3, 6, and 12 months of SCIG replacement treatment.Results: Local reactions were high at the beginning, then decreased with recurrent infusions. Any severe systemic reactions were not observed in patients. Less infection rate was seen in four patients who were not receiving IVIG regularly before with good compliance in all patients. Infection frequency remained same in 4patients. Increased levels of IgG were achieved eight of the patients at end ofthe 6months and their levels remained as stable at the end of a year.Conclusion: Our study showed that rapid SCIG therapy in same monthly dose with IVIG is as effective as IVIG for preventing infections without any worse systemic reactions.

PDF

___

Vultaggio A, Azzari C, Milito C, Finocchi A, Toppino C, Spadaro G, et al. Subcutaneous ımmunoglobulin replacement therapy in patients with primary immunodeficiency in routine clinical practice: The VISPO prospective study. Clin Drug Investig 2015;35(3):179-85.
Jolles S, Orange JS, Gardulf A, Stein MR, Shapiro R, Borte M, et al. Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodefciency disease. Clin Exp Immunol 2015; 179(2):146-60.
Fadeyi M, Tran T. Calculating the dose of subcutaneous immunoglobulin for primary immunodefciency disease in patients switched from intravenous to subcutaneous immunoglobulin without the use of a dose-adjustment coeffcient. PT 2013;38:768-70.
Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodefciency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol 2008;122(1):210-2.
Orange JS, Belohradsky BH, Berger M, Borte M, Hagan J, Jolles S, et al. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin Exp Immunol 2012;169 (2)172-81.
Haddad E, Berger M, Wang ECY, Jones CA, Bexon M, Baggish JS. Higher Doses of Subcutaneous IgG Reduce Resource Utilization in Patients with Primary Immunodefciency. J Clin Immunol 2012;32(2):281-9.
Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M; Subcutaneous IgG Study Group. Safety and effcacy of selfadministered subcutaneous immunoglobulin in patients with primary immunodefciency diseases. J Clin Immunol 2006;26(3):265-73.
Gardulf A, Nicolay U, Asensio O, Bernatowska E, Böck A, Carvalho BC, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodefciencies a prospective, multi national study. J Clin Immunol 2006;26(2):177-85.
Wasserman RL, Irani AM, Tracy J, Tsoukas C, Stark D, Levy R, et al. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purifed in patients with primary immunodefciency disease. Clin Exp Immunol 2010;161(3):518-26.
Karakoc Aydiner E, Kıykım A, Barıs S, Özen A, Barlan I. Use of subcutaneous immunoglobulin in primary immune deficiencies. Turk Pediatri Ars 2016;51(1):8-14.
Berger M. Choices in IgG replacement therapy for primary immune defciency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose. Curr Opin Allergy Clin Immunol 2011;11(11):532-8.
Šedivá A, Chapel H, Gardulf A; European Immunoglobulin Map Group (35 European Countries) for European Society for Immunodefciencies (ESID) Primary Immunodefciencies Care in Development Working Party. Europe immunoglobulin map. Clin Exp Immunol 2014;178:141-3.
EMEA Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the clinical investigation of human normal immunoglobulin for subcutaneous and intramuscular use (CPMP/BPWG/283/00). London: European Agency for Evaluation of Medicinal Products; 2002.
Aebersold P. In: Intravenous immunoglobulins in the 21st century: progress and challenges in effcacy, safety and paths to licensure. Bethesda (MD): FDA Workshop, 2005.
Gardulf A, Nicolay U, Math D, Asensio O, Bernatowska E, Böck A, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self- infusions at home. J Allergy Clin Immunol 2004;114(4):936-42.
American Academy of Allergy Asthma and Immunology. Eight guiding principles for effective use of IVIG for patients with primary immunodefciency. USA: Milwaukee, 2011.
Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodefciency. Immunol Allergy Clin North Am 2008;28(2):413-37.
Gardulf A. Immunoglobulin treatment for primary antibody defciencies: advantages of the subcutaneous route. BioDrugs 2007;21(2):105-16.
Shapiro R. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis. J Clin Immunol 2010;30(2):301-7.
Berger M. Subcutaneous immunoglobulin replacement in primary immunodefciencies. Clin Immunol 2004;112(1):1-7.
Albin S, Cunningham-Rundles C. An update on the use of immunoglobulin for the treatment of immunodeficiency disorders. Immunotherapy 2014;6(10):1113-26.
Wood P. Primary antibody deficiency syndromes. Ann Clin Biochem 2009;46(Pt 2):99-108.
Patiroglu T, Akar H, Unal E, Ozdemir MA, Karakukcu M,, Patıroglu TE. Malignancies in Primary Immunodeficiencies: A Single Center Experience. Pediatr Allergy Immunol and Pulmonol 2015;28(1):47-54.
Patiroglu T, Gungor HE, Unal E. Autoimmune diseases detected in children with primary immunodeficiency diseases: results from a reference centre at middle anatolia. Acta Microbiol Immunol Hung 2012;59(3):343-53.
Jyothi S, Lissauer S, Welch S, Hackett S. Immune deficiencies in children: an overview. Arc Dis Child Educ Pract Ed 2013;98(5):186-96.